Roland Phillips, MD
Cardiovascular Disease · Saratoga Springs, NYNPI 1508834060
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Amgen at 43.3% of the total. Reporting peaked in 2020 at $4,935 and has fallen 86.6% since, to $660 in 2025.
Across 431 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Novartis$1K
- Pfizer$767
- Boehringer Ingelheim$595
- Merck$466
- E.r. Squibb & Sons, L.L.C.$336
- plus $3K from 28 others
Across 306 payments — averaging $1046.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$131K
- Takeda Pharmaceuticals U.S.A., Inc.$72K
- Bayer$44K
- Amgen$40K
- Novartis$17K
- AstraZeneca$13K
- plus $4K from 1 others
What the payments were for
- Consulting fees$4,50040%
- Food & beverage$6,53559%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $4,809 |
| Novartis | 131 | $1,389 |
| Pfizer | 44 | $767 |
| Boehringer Ingelheim | 37 | $595 |
| Merck | 27 | $466 |
| E.r. Squibb & Sons, L.L.C. | 20 | $336 |
| Novo Nordisk | 15 | $302 |
| Alnylam Pharmaceuticals Inc. | 13 | $297 |
| Johnson & Johnson | 25 | $295 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $204 |
| Sanofi-aventis U.S. LLC | 9 | $194 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $192 |
| AstraZeneca | 13 | $191 |
| Scpharmaceuticals Inc. | 8 | $157 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $131 |
| Bayer | 5 | $104 |
| Astellas Pharma US Inc | 2 | $87 |
| Abiomed | 3 | $81 |
| Sanofi | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $67 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Amarin Pharma, Inc. | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Gilead | 1 | $11 |
| Philips North America LLC | 1 | $11 |
How this compares
$11,113 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 613 | $855,433 |
| Repatha SureclickEvolocumab | 170 | $164,438 |
| XareltoRivaroxaban | 105 | $144,864 |
| EntrestoSacubitril/Valsartan | 130 | $136,656 |
| Praluent PenAlirocumab | 73 | $58,283 |
| MultaqDronedarone Hcl | 25 | $44,809 |
| JardianceEmpagliflozin | 18 | $27,572 |
| FarxigaDapagliflozin Propanediol | 11 | $17,962 |
| Ranolazine ErRanolazine | 144 | $17,007 |
| Rosuvastatin Calcium | 1,042 | $16,965 |
| Ezetimibe | 267 | $10,288 |
| Metoprolol Succinate | 522 | $8,794 |
| Atorvastatin Calcium | 625 | $8,258 |
| Icosapent Ethyl | 19 | $6,225 |
| Torsemide | 319 | $4,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $767 | $855,433613 claims |
| Johnson & JohnsonXarelto | $295 | $144,864105 claims |
| NovartisEntresto | $1,389 | $136,656130 claims |
| Sanofi-aventis U.S. LLCMultaq | $194 | $44,80925 claims |
| Boehringer IngelheimJardiance | $595 | $27,57218 claims |
| AstraZenecaFarxiga | $191 | $17,96211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Saratoga Springs
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.